CASP3 and chronic myelogenous leukemia, BCR-ABL1 positive: Combinations of nilotinib with VEN resulted in significantly more PS presentation than nilotinib alone in the lymphoid BP-CML cell lines BV173 (nilotinib: 12 ± 4.46%; nilotinib+VEN: 89.49 ± 2.09%; p < 0.0001) and CML-T1 (nilotinib: 13.69 ± 2.05%; nilotinib + VEN: 27.49 ± 2.76%; p = 0.0023) (Fig. 6C), and a greater degree of caspase-3 activation in KCL-22 (nilotinib: 10.92 ± 6.23%; nilotinib + VEN: 60.27 ± 15.01%; p = 0.0006) and BV173 cells (nilotinib: 15.84 ± 2.83%; nilotinib+VEN: 89 ± 0.83%; p = 0.0006) (Fig. 6D).